Exploring the Therapeutic Potential of Cannabinoids in Neurological Disorders

Neurological disorders encompass a broad spectrum of conditions ranging from epilepsy to Alzheimer's disease, each presenting unique challenges in treatment and management. Over recent years, there has been growing interest in the therapeutic potential of cannabinoids, compounds derived from the Cannabis sativa plant, in addressing these disorders. This abstract delves into the current state of research surrounding the use of cannabinoids in neurological disorders, focusing on their mechanisms of action, efficacy, and safety profiles. Cannabinoids interact with the endocannabinoid system, a complex network of receptors and neurotransmitters involved in regulating various physiological processes, including neuronal function and inflammation. Through their modulation of this system, cannabinoids exert diverse effects on neurological function, offering promise in alleviating symptoms associated with neurological disorders. Epilepsy, for instance, has garnered considerable attention due to the success of cannabidiol (CBD), a non-psychoactive cannabinoid, in reducing seizure frequency and severity in certain forms of the condition. Additionally, cannabinoids have shown potential in managing symptoms of neurodegenerative diseases like Parkinson's and Alzheimer's, with evidence suggesting neuroprotective properties and the ability to mitigate neuroinflammation and oxidative stress. However, despite promising preclinical and clinical findings, challenges remain in fully harnessing the therapeutic potential of cannabinoids. Regulatory hurdles, variability in cannabinoid formulations and dosages, and limited understanding of long-term effects pose significant barriers to widespread adoption. Furthermore, the psychoactive properties of some cannabinoids, notably delta-9-tetrahydrocannabinol (THC), necessitate careful consideration of potential cognitive and psychomotor side effects.